Navigation Links
Amarantus BioSciences Appoints Dr. Robert J. Zimmerman as Product Development Advisor
Date:11/12/2012

SUNNYVALE, Calif., Nov. 12, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it has appointed Robert J. Zimmerman, SD as product development advisor. In Dr. Zimmerman's advisory role, he will assist Amarantus management with expansion of the Company's MANF product development strategy. Dr. Zimmerman will also assist in the procurement of relationships with top-tier vendors to ensure that state-of-the art development data are gathered with high quality test article materials. Amarantus expects to gather data in additional indications through its research grant with the Center of Excellence in Apoptosis Research, collaboration with highly-respected academic labs, and through outsourcing efficacy and toxicology studies with independent contract labs.

"I have been involved with Amarantus formally and informally for the past three years supporting the founders as they work tirelessly to advance MANF to a stage where it has real commercial potential," said Robert J. Zimmerman, SD. "While that effort has been centered on Parkinson's disease, I believe additional opportunities exist to diversify this therapeutic candidate. Ischemia/reperfusion, cardiovascular disease, stroke, traumatic brain injury, diabetes and potentially other disease conditions appear to be impacted by MANF based upon preclinical studies and the literature."

Dr. Zimmerman is currently a biopharmaceutical product development consultant in the Bay Area at Zimmerman Consulting. Prior to starting his company, Dr. Zimmerman held senior management positions at Signature BioScience, Inc. where he served as Chief Operating Officer and as President, overseeing all research and development activities.  Previously, he served as Vice President of Biotechnology Research at B
'/>"/>

SOURCE Amarantus BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
2. Amarantus BioSciences Announces MANF Demonstrates Superiority over GDNF in Neurorestoration Behavioural Animal Model of Parkinsons Disease
3. Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
4. Amarantus Biosciences and RBCC Outline Terms for NuroPro Parkinsons Blood Test Joint Venture
5. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
7. Neurocrine Biosciences Reports First Quarter 2012 Results
8. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
9. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
10. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
11. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... ANGELES , May 24, 2013  An international ... on Saturday, May 18, in Santa Monica, ... on new lung-sparing therapies for MPM, a rare form ... commonly affects the pleura, the lining of the chest. ... Lung and Blood Institute, the 3rd Annual International Symposium ...
(Date:5/24/2013)... May 24, 2013  Auxilium Pharmaceuticals, Inc. (Nasdaq: ... participate in the Deutsche Bank Health Care Conference to ... Hotel.  Mr. Adrian Adams , Chief ... overview of the Company and its product pipeline at ... (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) The ...
(Date:5/24/2013)... The potential of the pulmonary ... therapeutic agents has been receiving undeniable attention with the ... promise. The crucial formulation considerations for orally inhaled products ... major role in the efficiency of pulmonary delivery, and ... new formulation techniques and devices in recent years. ...
Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2
... 9, 2008 Intra-Cellular Therapies, Inc.,today announced ... for ITI-007, the Company,s first-in-class dual 5HT2A ... low-dose formulation of ITI-007, which are in ... new data demonstrate,ITI-007 has preclinical activity both ...
... Kinase Inhibitor Phase 1 Trial in Advanced ... 2008 EntreMed, Inc.,(Nasdaq: ENMD ), ... treatment of cancer and inflammatory diseases, today,announced ... dose-escalation study for its,selective kinase inhibitor, ENMD-2076, ...
Cached Medicine Technology:Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722 2Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722 3EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 2EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 3EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 4
(Date:5/24/2013)... May 24, 2013 CHI-California Healthcare ... and the California congressional delegation, joined by over ... industry user fees paid to the U.S. Food ... that future across-the-board cuts will not include user ... FY14 Agriculture, Rural Development and FDA Appropriations Bill. ...
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- Drugs commonly used ... side effects that can interfere with vision, according to ... analogues (PGAs), which are used to reduce eye pressure, ... and changes in eye color, the researchers said, suggesting ... for PGAs. Doctors should be conservative when ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Let’s face it: ... is not uncommon for the majority of people to be ... is due to a coffee addiction or simply genetics, yellowish ... procedures are so popular. , Herald Square Dental ... very effective whitening system: Venus White Max. , Teeth ...
(Date:5/24/2013)... 24, 2013 Area homeowners dreaming about owning ... hot tubs to choose from at factory-direct pricing during the ... sales event takes place at Emerald Pool and Patio ... , Jacuzzi, the industry's leading hot tub brand, scheduled the ... country. The event will feature popular hot tub models at ...
(Date:5/24/2013)... York, New York (PRWEB) May 24, 2013 ... Vinci lawsuit involving Intuitive Surgical Inc.’s da Vinci ... According to court records, a Washington State Court jury ... committed negligence in training a surgeon who performed a ... years later. The patient’s family had alleged in ...
Breaking Medicine News(10 mins):Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 2Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 3Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Herald Square Dental Introduces New In-office Whitening System: Venus White Max 2Health News:Truckload of Jacuzzi® Hot Tubs Rolls into Bend, Oregon on May 24, 2013 for Sales Event 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 3
... Senetek PLC (OTC,Bulletin Board: SNKTY), a Life ... target the science of healthy aging, today announced,the ... ., Mr. Frank Massino, Senetek,s Chairman and ... greater visibility to Senetek at this,significant time in ...
... good models for human biology and disease. Now, ... that is transparent throughout its life. The new ... and observe processes like tumor metastasis and blood production ... fish, described in the February 7 issue of Cell ...
... Prescription pediatric drugs represent,an enormous market, with manufacturer sales ... forecast at a modest 3.2%, reaching $43,billion by 2011, ... 11.7%, is,expected to achieve the highest growth rate of ... new report The World Market for,Pediatric Drugs., The ...
... N.C., Feb. 6 With pharmaceutical sales,forces shrinking ... force will be a key driver in organizational ... structure conducive to motivating sales people,properly communicating goals ... both,organizational and personal goals., The Best Practice ...
... 6 Nile Therapeutics,Inc. (OTC Bulletin Board: NILT), ... been dosed in its Phase Ib, multi-center, open-label,ascending ... candidate,CD-NP, a novel chimeric natriuretic peptide, in development ... "We are very excited that dosing has begun ...
... to seek restatement of Beth Israel Deaconess,Medical Center audit, ... Douglas T. Linde should apply the same Sarbanes-Oxley,standards used ... role on the board of Beth Israel Deaconess Medical ... Workers East. Linde is,also the president and CFO of ...
Cached Medicine News:Health News:Senetek PLC Announces Launch of New Website 2Health News:Transparent fish to make human biology clearer 2Health News:Transparent fish to make human biology clearer 3Health News:Diabetes, Growth Disorders Drive Sales of Pediatric Hormone Drugs 2Health News:Best Practice Database: Complimentary Excerpt of Three Sales Force Excellence Studies 2Health News:Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP 2Health News:Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP 3Health News:Boston Properties Executive and Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: